Optic Inc. is a pioneering startup that merges biotechnology with artificial intelligence (AI) to create innovative tools and drugs aimed at revolutionizing the drug discovery process. Founded by Andrey Doronichev, a serial tech entrepreneur and former Director of Product at Google, along with Vlad Vinogradov, an AI research lead with a decade of experience, and Roman Doronin, a lab operation leader and former CEO of EORA, the company boasts a strong leadership team with a wealth of experience in both tech and biotech sectors.

Optic Inc. operates in the pharmaceutical and biotechnology market, serving pharmaceutical companies, research institutions, and biotech firms. The company's flagship product, the BIOPTIC AI Engine, utilizes deep learning—a type of machine learning that mimics the human brain—to identify molecules with similar activities. This capability significantly enhances the speed and efficiency of drug discovery, allowing researchers to discover, collect, and explore diverse molecules more quickly than traditional methods.

The business model of Optic Inc. is centered around providing subscription-based access to its AI-powered tools and platforms. Clients pay for the ability to use the BIOPTIC AI Engine to accelerate their drug discovery processes. Additionally, Optic may offer custom solutions and consulting services tailored to the specific needs of their clients, further diversifying their revenue streams.

Optic Inc. makes money primarily through subscription fees for its AI tools, consulting services, and potentially through partnerships or licensing agreements with larger pharmaceutical companies. By offering a cutting-edge solution that addresses a critical need in the drug discovery process, Optic Inc. positions itself as a valuable partner in the biotech and pharmaceutical industries.

Keywords: Biotechnology, Artificial Intelligence, Drug Discovery, Deep Learning, Molecule Search, Pharmaceutical, Research, Subscription Model, Consulting Services, Innovation.